20 results about "ARDS" patented technology

The application relates to kaempferol cerium nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines. The kaempferol cerium nanoparticles are prepared by performing coordination co-assembly on kaempferol and cerium ions in the presence of polyethylene glycol at a specific molar ratio, and the nanoparticles have uniform particle sizes and good dispersity. The nanoparticles have the anti-inflammatory activity of kaempferol and the ROS scavenging capacity of cerium ions, and show a significant synergistic effect in in-vivo and in-vitro experiments, can effectively reduce lung inflammation, inhibit oxidative stress, improve lung function, and have good biological safety, thereby providing a new drug candidate scheme for the treatment of ARDS.

The application discloses a lung inflammation lesion quantitative evaluation artificial intelligence model based on CT images and relates to the field of artificial intelligence models.The model comprises CT image preprocessing, self-supervised lesion segmentation and quantification, multi-modal joint pre-training coding and multi-task diagnosis and prognosis prediction module composition which are sequentially and communicatively connected, and realizes feature interaction through a unified feature embedding space.The model realizes self-supervised lesion segmentation and multi-dimensional quantification by adopting a three-dimensional generative reconstruction network, completes image-text feature fine-grained alignment through cross-modal contrast learning of an adversarial enhancement, and fuses multi-dimensional features.The model can complete multiple tasks such as ARDS diagnosis, non-invasive estimation of P / F ratio, severity grading and prognosis prediction in parallel, reduces dependence on artificial labeling, improves cross-center generalization capability and diagnosis precision, and provides a standardized intelligent tool for clinical evaluation of severe lung inflammation.

The application provides a use of a teriparatide acetate in preparation of a medicine for preventing and / or treating acute respiratory distress syndrome, and belongs to the technical field of medicines.The application finds that after a mouse with acute respiratory distress syndrome (ARDS) is injected with the teriparatide acetate, neutrophil infiltration can be effectively reduced, and lung hemorrhage, lung capillary hyperemia and lung capillary septum thickening and other lung injury symptoms can be reduced.In addition, the teriparatide acetate can effectively prevent the occurrence of ARDS, can reduce the lung injury degree of the mouse, can reduce the neutrophil infiltration, lung hemorrhage and lung capillary hyperemia and other symptoms, can reduce the level of inflammatory factors in serum, and can reduce lung edema.Therefore, the teriparatide acetate can not only be used for treating acute respiratory syndrome and acute lung injury, but also can prevent the occurrence and development of acute respiratory syndrome, has a remarkable effect, is high in safety, and has a wide application prospect.

This invention discloses the application of rhubarb-derived exosome-like nanovesicles in the preparation of a drug for treating acute respiratory distress syndrome (ARDS) induced by severe acute pancreatitis, belonging to the field of nanomedicine technology. This invention is the first to propose the application of rhubarb-derived exosome-like nanovesicles in the preparation of a drug for treating ARDS induced by severe acute pancreatitis, providing a new method for treating ARDS and expanding the application of rhubarb-derived exosome-like nanovesicles in the pharmaceutical field. This invention is also the first to propose using rhubarb-derived exosome-like nanovesicles as the active ingredient in a pharmaceutical composition for treating ARDS induced by severe acute pancreatitis.

The application discloses application of a group of clinical indexes in preparation of a product for subtyping of ARDS patients complicated with AKI, and constructs a Transformer model for subtyping of ARDS patients complicated with AKI and an ARDS patient complicated with AKI subtyping device based on the Transformer model in combination with the clinical indexes. The ARDS patient complicated with AKI subtyping device can realize accurate and automatic subtyping of ARDS patients complicated with AKI, effectively divides the ARDS patients complicated with AKI into three subtypes with different disease progressions, and then realizes individualized treatment of ARDS patients complicated with AKI with different disease progressions, and the subtyping result has excellent generalization and clinical interpretability.

Methods of improving ARDS by regulating a stellate ganglion is provided herein. Methods of improving a hypercoagulation state are also provided by regulating the sympathetic nervous system.

Disclosed are glycan compounds and their use for treating or inhibiting the development of a viral infection, in particular a coronavirus infection, such as a SARS-CoV-2 infection, in a subject, or for treating a condition associated with a viral infection, such as an acute inflammatory condition, cytokine release syndrome (CRS) or cytokine storm, severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS).

The present invention relates to a composition for use in treating a subject suffering from acute respiratory distress syndrome (ARDS), wherein the subject is suffering from a viral infection and wherein the composition comprises a combination of effective amount of the free fatty acids oleic acid, linoleic acid, and palmitic acid.

The invention belongs to the field of biological medicine, and particularly relates to application of an ADAM10-targeted inhibitor to treatment or prevention of inflammation caused by virus infection. Specifically, abnormal fusion between immune cells (such as mononuclear cells and macrophages) and infected pulmonary epithelial cells in the virus infection process and excessive activation caused by the abnormal fusion can be specifically blocked by inhibiting activity or expression of ADAM10, so that generation of proinflammatory cytokines (such as IL-6, IL-1beta and TNF-alpha) is effectively reduced. The methods are particularly useful in the treatment or prevention of inflammatory responses induced by viral infections and related inflammatory diseases, such as viral pneumonia and acute respiratory distress syndrome. Compared with a broad-spectrum immunosuppressor, the invention provides a novel anti-inflammatory treatment strategy with stronger targeting property and smaller potential side effect.

This invention discloses the application of a SNP in the SLC39A1 gene in assessing susceptibility risk for acute respiratory distress syndrome (ARDS) in children. The SNP is a non-coding variant, with the variant sites being rs6724, rs11264734, or / and rs12027783 in the SLC39A1 gene. This SNP in the SLC39A1 gene can serve as a genetic marker for ARDS susceptibility in children, used for clinical prediction of ARDS risk, severity, and prognosis. It facilitates early and accurate stratification of high-risk children and prediction of severity, providing a basis for personalized precision treatment.

This invention relates to a mitochondrial composite nanosystem DTPS@Mito targeting lung inflammation, comprising a mitochondrial core and a functionalized lipid material DSPE-TK-PEG2000-SA modified on its surface. DSPE acts as a hydrophobic anchor inserted into the mitochondrial outer membrane, PEG2000 provides hydrophilicity and biocompatibility, ketithiothiol bonds serve as ROS-responsive linkers, and sialic acid targets the head group to specifically bind to E-selectin, which is highly expressed at the inflammatory site. The DTPS@Mito particles have a diameter of approximately 832 nm, maintaining intact mitochondrial morphology and protein composition. In vitro experiments show that it significantly inhibits the expression of inflammatory factors, reduces ROS levels, restores ATP production, and regulates mitochondrial dynamics. In vivo experiments show that it has enhanced retention and accumulation capacity in the lungs of ARDS mice, significantly alleviating lung inflammation, tissue damage, and oxidative stress, and reducing hyaline membrane formation. This invention achieves the synergistic integration of three major functions: mitochondrial transplantation, targeted delivery, and antioxidation, and can be used to prepare drugs for the treatment of acute respiratory distress syndrome.

The present disclosure relates, at least in part, to compositions comprising constant natural killer T (iNKT) cells (e.g., unmodified allogeneic iNKT cells), and uses of the compositions comprising the iNKT cells to treat a disease or a symptom or complication of a disease (e.g., a viral infection, a disease secondary to a primary disease (e.g., a neurological disease). The present invention relates to a method for treating acute respiratory distress syndrome (ARDS) and / or organ failure associated therewith (e.g., viral infection).

This invention discloses a mitochondrial uncoupling agent prodrug with endothelial cell targeting, its preparation method, and its application, relating to the field of biomedical technology. The prodrug is covalently coupled to a vascular cell adhesion molecule-1 targeting polypeptide (amino acid sequence FAKELMEEFEKW), a reactive oxygen species-sensitive thioacetate linker, and the mitochondrial uncoupling agent OPC-163493. This invention utilizes the active enrichment effect of the targeting polypeptide on inflamed pulmonary vascular endothelial cells, overcoming the off-target defects of non-specific distribution in existing small molecule drugs; simultaneously, it utilizes the specific cleavage characteristics of the thioacetate linker in a microenvironment rich in reactive oxygen species to achieve precise in-situ drug release. This prodrug can effectively reduce mitochondrial reactive oxygen species generation, inhibit endothelial cell apoptosis, significantly reduce pulmonary vascular permeability, and alleviate pulmonary edema, possessing significant clinical application value in the preparation of drugs for treating acute lung injury or acute respiratory distress syndrome.

The present invention relates to compounds of formula (I) as GPR65 modulators for the treatment of a proliferative disorder, such as e.g. cancer, an immune disorder, asthma, chronic obstructive pulmonary disease (CORD) or acute respiratory distress syndrome (ARDS). Preferred compounds are e.g. N-(Pyridin-2-yl)-6,7,8,9-tetrahydro-5H-5,8-epiminocyclohepta[c]pyridine-10-carboxamide derivatives and similar compounds, such as e.g. (5R,8S)—N-(4-chloro-5-(trifluoromethyl)pyridin-2-yl)-1-fluoro-6,7,8,9-tetrahydro-5H-5,8-epiminocyclohepta[c]pyridine-10-carboxamide (compound 1)

The application discloses a research method for the mechanism of CXCR3A in acute respiratory distress syndrome, and relates to the technical field of biomedicine; and comprises the following steps: establishing an animal ARDS model and setting an intervention group; experiment animals are randomly divided into at least four groups, namely a normal control group, an ARDS model group, a CXCR3 broad-spectrum inhibitor intervention group and a CXCR3A selective inhibitor intervention group; a damaging agent is applied to the model group and the two inhibitor intervention groups of animals to establish an ARDS model; the CXCR3 broad-spectrum inhibitor intervention group and the CXCR3A selective inhibitor intervention group are respectively pretreated with corresponding inhibitors before modeling. The method of the application constructs a complete research framework from the whole animal level to the molecular level, covers multiple key aspects of pathological morphology, inflammatory response, oxidative stress and target gene expression, and can reveal the comprehensive mechanism of CXCR3A in the occurrence and development of ARDS.

The application relates to application of a peppermint-derived exosome in preparation of a medicine for treating LPS-induced ARDS, and the peppermint-derived exosome is obtained through treatment such as soaking in a PBS solution, wall breaking, differential centrifugation, filtration, ultracentrifugation, sucrose density gradient centrifugation and the like. The peppermint-derived exosome in the application can not only reduce histological damage of lung tissue of LPS-induced ARDS mice, improve pulmonary edema, but also has an anti-inflammatory effect on the lung of the ARDS mice, so that the peppermint-derived exosome can be used for preparing a medicine for treating LPS-induced ARDS.

Provided herein is a method for one or mor of preventing, treating, reducing the severity of acute respiratory distress syndrome (ARDS) in a subject at risk for contracting ARDS and infected with a coronavirus or SARS-CoV-2, comprising administering to the subject metformin, an analog or a derivative thereof, thereby preventing, treating, or reducing the severity of ARDS in the subject.

The application belongs to the technical field of new application of medicines, and particularly relates to hydroxycinnamic acid derivatives, a preparation method and application thereof. The ARDS model is induced by LPS tracheal instillation combined with hydroxycinnamic acid derivatives, the alveolar lavage fluid cell count is determined, and the pathological characteristics and the expression level of inflammatory genes of lung tissues are detected; the results show that the hydroxycinnamic acid derivatives can significantly reduce lung cell infiltration, alleviate lung tissue damage and reduce the expression level of inflammatory factors.

The utility model discloses a kind of chest drainage tube for monitoring intrapleural pressure, comprising: drainage tube body, for inserting intrapleural, and outlet end are equipped on drainage tube body;First pressure sensor, set on the one side of the insertion end on the outer periphery of the drainage tube body, for real-time monitoring the pressure value in pleural cavity, the first pressure sensor is electrically connected with signal transmission device;Signal transmission device, for receiving the pressure signal transmitted by the first pressure sensor, and the signal is transmitted to external display unit;Drainage hole, set on the pipe wall of the insertion end of the drainage tube body, for draining effusion or gas in pleural cavity.The utility model can monitor intrapleural pressure in real time accurately, understand patient spontaneous breathing intensity, calculate transpulmonary pressure and transpulmonary driving pressure, guide the treatment of acute respiratory distress syndrome patient, breathing machine setting and patient offline extubation process.

This invention provides methods for treating acute respiratory distress syndrome (ARDS), including ARDS associated with respiratory viral infections. [Solution] Administer plasma kallikrein (pKal) inhibitors such as anti-pKal antibodies as inhibitors of the contact activation pathway. Immunomodulators such as IL-6R inhibitors, antiviral agents such as lopinavir, ritonavir, interferon beta, umfenovir, and remdesivir, antimalarial agents such as chloroquine, and / or inhibitors of the contact activation pathway such as C1 inhibitors, pKal inhibitors, and bradykinin receptor antagonists may be administered to the patient as additional therapeutic agents.